Primary reference for these deficiencies: Parks et al., 2004. This Exelixis deletion collection was generated in an isogenic background and provides ~56% coverage of the euchromatic genome. An overview from Exelixis as of 2004 is presented in this slide presentation. See also Cook et al. 2012 and Roote & Russell 2012.
Some restrictions apply to the distribution and use of deletion lines from Exelixis. Commercial researchers must obtain a use license from Exelixis Inc. to work with these stocks.

The entry in the Basis column below indicates how the stock center updated breakpoint sequence coordinates:
R5 flank = insertion flanking sequence aligned to release 5 genome assembly (per FlyBase or R. Hoskins, personal communication)
R3 author statement->R5 = Parks et al. release 3 sequence coordinate mapped forward to release 5
A single entry in Basis applies to both endpoints; two values indicate the basis of left and right endpoints, respectively.
Values based on R3 author statements should be treated as approximations.

Our complementation tests have shown that 10% of the stocks in the original Exelixis deletion collection did not carry the described deletion and that 77% of the stocks are deficient. The remaining 13% are unconfirmed.

Df-Genes Table	Link to an Excel file depicting the endpoints of the Exelixis deficiencies relative to R3 sequence-mapped genes.
Deletion Coverage	Link to maps of deletion coverage generated by the DrosDel Project.
Generating Deletions	Link to information on generating similar deletions.